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Effective	 medical	 treatment	 for	 thyroid	 eye	 disease,	 a	 debilitating	 condition	 which	 may	
cause	 sight-loss,	 has	 been	 lacking.	 A	 recent	 phase	 III	 trial	 of	 Teprotumumab,	 an	 IGF1R	
antagonist,	reports	most	encouraging	results	–	may	be	a	game-changer?		The	trial	is	put	in	
the	context	of	current	management	strategies	to	address	this	question.		
Refers	to	Douglas,	R.	S.	et	al.	Teprotumumab	for	the	treatment	of	active	thyroid	eye	disease.	
N.	Engl.	J.	Med.	382,	341–352	(2020).	
	
Graves	orbitopathyalso	known	as	thyroid	eye	disease	(TED)	and	thyroid	associated	ophthalmopathy	
(TAO),	 remains	 one	 of	 the	 last	 great	 challenges	 in	 endocrinology1,	 but	 that	 might	 be	 about	 to	
change.	A	study	published	in	January	2020,	in	the	New	England	Journal	of	Medicine,	reports	a	phase	
III	clinical	trial	of	teprotumumab	for	the	treatment	of	active	TED.	The	randomized,	multicentre	trial	
recruited	 41	 and	 42	 patients	 who	 received	 infusions,	 at	 3	 week	 intervals	 for	 21	 weeks,	 of	
teprotumumab	 (10	 mg/kg	 then	 20	 mg/kg	 bodyweight)	 or	 placebo,	 respectively2.	 The	 primary	
outcome	was	 a	 reduction	 of	 >2mm	 in	 proptosis.	 At	week	 24,	 83%	 of	 the	 patients	who	 had	 been	
treated	with	teprotumumab	had	achieved	the	primary	outcome,	compared	with	10%	of	the	placebo	
group.	More	encouragingly,	teprotumumab	treatment	was	free	of	serious	adverse	effects	and	also	
statistically	 significantly	 improved	 all	 secondary	 outcomes,	 including	 overall	 response	 rate,	 clinical	
activity	score,	diplopia	response	rate	and	improvements	in	the	Graves	orbitopathy-specific	quality	of	
life	questionnaire.		
	
Teprotumumab	is	a	human	monoclonal	antibody	to	insulin-like	growth	factor	1	receptor	(IGF1R)	that	
was	originally	developed	for	the	treatment	of	solid	tumours.	It	is	highly	selective	and	blocks	receptor	
activation	 directly,	 by	 inhibiting	 binding	 of	 ligands	 such	 as	 IGF1,	 and	 indirectly	 by	 receptor	
internalization3.	 Ray	 Douglas	 and	 Terry	 Smith,	 the	 lead	 and	 senior	 authors	 of	 the	 study,	 have	
described	 the	 central	 role	 of	 the	 IGF1R	 in	 TED	 pathogenesis4,	 in	 which	 expansion	 of	 the	 orbital	
tissues	 in	 the	 confines	 of	 a	 bony	 orbit,	 by	 excess	 adipogenesis	 (generation	 of	 new	 adipocytes	 by	
differentiation)	 and	 over-production	 of	 glycosaminoglycans	 (especially	 hyaluronan),	 leads	 to	
proptosis.	 Smith	 and	 colleagues	 demonstrated	 that	 IGF1	 and	 Graves	 immunoglobulins	 (which	 are	
distinct	from	the	thyroid	stimulating	antibodies	(TSAB)	that	cause	hyperthyroid	Graves	disease)	were	
able	to	increase	production	of	inflammatory	cytokines	and	hyaluronan	by	orbital	fibroblasts	and	also	
to	 enhance	 orbital	 fibroblast	 proliferation.	 However,	 it	 must	 be	 noted	 that	 evidence	 for	
autoantibodies	 to	 the	 IGF1R	 being	 more	 abundant	 in	 people	 with	 TED	 than	 healthy	 controls	 is	
controversial,	as	is	the	ability	of	autoantibodies	to	activate	the	receptor	by	phosphorylation5.		
	
The	phase	III	trial	confirmed	and	extended	the	phase	II	results;	however,	in	the	latter	trial	proptosis	
was	a	component	of	the	primary	outcome	rather	than	being	the	sole	primary	outcome	6.	More	than	
80	 patients	 with	 TED	 have	 been	 treated	 with	 teprotumumab	 and	 the	 longer-term	 follow-up	 of	
outcomes,	particularly	relapse	rate,	is	eagerly	awaited.	
	
TED	 is	 a	 rare	 autoimmune	 condition	 that	 predominantly	 affects	 women,	 in	 whom	 the	 cosmetic	
effects	 have	 at	 least	 the	 same	 negative	 effect	 on	 quality	 of	 life	 as	 vision	 disturbance1.	 A	 major	
strength	of	the	study	is	that	recruitment	at	13	sites	enabled	the	required	number	of	patients	to	be	
randomized	in	less	than	a	year.	The	inclusion	and	exclusion	criteria	were	appropriately	rigid	but	the	
cohort	investigated	showed	some	anomalies;	for	example,	a	lower	than	usual	percentage	of	smokers	
in	 both	 treatment	 groups	 (smoking	 is	 a	 major	 risk	 factor	 for	 TED7	 but	 strategies	 to	 encourage	
quitting	meet	with	measured	success)	and	several	individuals	who	might	have	been	overweight	(the	
BMI	 was	 not	 provided)	 and	 experienced	 substantial	 weight	 loss	 following	 treatment	 with	
teprotumumab.		
	
The	majority	of	patients	with	TED	(>90%)	have	Graves	disease	yet	neither	the	phase	II	nor	phase	III	
trials	 have	 reported	 TSAB	 levels,	 whether	 their	 titre	 at	 baseline	 correlates	 with	 response	 to	
teprotumumab	or	whether	TSAB	 levels	are	affected	by	the	treatment.	TSAB	are	highly	relevant,	as	
illustrated	by	the	fact	that	patients	with	Graves	disease	who	have	the	highest	levels	of	TSAB,	or	who	
relapse	 following	 anti-thyroid	 drug	 therapy,	 are	 most	 likely	 to	 develop	 TED1.	 Some	 of	 the	 trial’s	
authors	and	other	groups8	have	reported	on	possible	cross-talk	between	the	IGF1R	and	the	target	of	
TSAB,	 the	 thyrotropin	 receptor	 (TSHR)	 in	 TED	 pathogenesis.	 Indeed,	 TSHR	 antagonism,	 using	 a	
monoclonal	 antibody	 (lacking	 stimulating	 activity)	 derived	 from	 a	 patient	 with	 Graves	 disease,	
ameliorated	 both	 Graves	 disease	 and	 TED	 in	 an	 unusual	 patient	 who	 also	 had	 follicular	 thyroid	
cancer9.	This	approach	will	need	to	be	tested	in	large	scale	controlled	trials	but	it	further	illustrates	
the	importance	of	the	TSHR	in	TED.	It	also	hints	at	how	teprotumumab	might	function	—	my	money	
is	 on	 the	 ability	 of	 the	 IGF1R	 antagonist	 to	 inactivate	 by	 receptor	 internalization	 rather	 than	 by	
interfering	with	ligand	binding.	In	all	honesty,	its’	mode	of	action	is	academic;	the	important	thing	is	
that	it	works!	
	Current	 TED	 treatment	 depends	 on	 whether	 the	 disease	 is	 mild,	 moderate	 to	 severe	 or	 sight	
threatening.	 Sight-threatening	 TED	 is	 due	 to	 compression	 of	 the	 optic	 nerve,	 occurs	 in	 <5%	 of	
patients	 and	 requires	 immediate	 surgical	 decompression1.	 In	 all	 patients	 with	 TED,	 restoring	 and	
maintaining	 euthyroidism	 should	 be	 a	 priority	 and	 smokers	 should	 be	 advised	 to	 stop	 smoking.	
Furthermore,	disease	management	 is	greatly	enhanced	by	 joint	clinics	with	an	endocrinologist	and	
an	ophthalmologist10.		In	most	patients	(>70%),	TED	is	mild	and	requires	only	local	measures	such	as	
synthetic	 tears	 and	 selenium.	 In	 moderate	 to	 severe	 disease	 the	 anti-inflammatory	 actions	 of	
intravenous	 glucocorticoids	 improve	 most	 of	 the	 signs	 and	 symptoms;	 however,	 relapse	 upon	
withdrawal	 is	 common	 but	 can	 be	 mitigated	 by	 the	 addition	 of	 an	 anti-proliferative	 such	 as	
mycophenolate10.	 Immunologics,	 such	as	 tocilizumab	 (an	anti-IL6	 receptor)	and	rituximab	 (an	anti-
CD20	that	depletes	B	cells)	and	orbital	radiotherapy	have	all	been	trialled	with	varying	success1.	Even	
when	 a	 stable	 inactive	 disease	 phase	 is	 reached,	 most	 people	 with	 TED	 require	 rehabilitative	
surgery,	 for	 example	 to	 improve	 cosmetic	 appearance	 and	 correct	 squint,	 the	 whole	 process	
requiring	several	years	to	complete.	
	
Throughout	 my	 career	 I	 have	 written	 that	 most	 of	 the	 signs	 and	 symptoms	 of	 TED,	 which	 have	
dramatic	negative	effects	on	vision,	appearance	and	quality	of	 life,	 can	be	attributed	 to	proptosis.	
The	 fact	 that	 a	medical	 treatment,	mainly	 free	of	 adverse	effects	 and	able	 to	 reduce	proptosis	 as	
efficiently	as	orbital	decompression	surgery	—	but	without	the	agonising	wait	—	is	now	available	is	
indeed	cause	for	optimism.	Teprotumumab	was	approved	by	the	FDA	in	2020;	but	people	with	TED	
outside	 the	 USA	might	 have	 to	 wait	 for	 the	 drug	 to	 be	 compared	with	 glucocorticoid	 treatment,	
which	has	been	the	mainstay	for	active	TED,	before	it	is	available	elsewhere.		
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Pullquotes		
At	 week	 24,	 83%	 of	 the	 patients	 who	 had	 been	 treated	 with	 teprotumumab	 had	 achieved	 the	
primary	outcome	
The	fact	that	a	medical	treatment	…	able	to	reduce	proptosis	…	is	now	available	is	indeed	cause	for	
optimism	
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